Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant

ACADIA PHARMACEUTICALS INC

Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.
She will stay through readout of Phase 2 remlifanserin in Alzheimer's disease psychosis and into early Phase 3.
Company has initiated a search for a new Head of R&D; all ongoing clinical trials continue as planned.
Thompson joined Acadia in 2024 and helped strengthen clinical capabilities and advance pipeline programs.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Elizabeth H.Z. Thompson

Head of Research and Development

ACAD · ACADIA PHARMACEUTICALS INC

Filed: May 1, 2026, 7:59 PM ET

On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elizabeth H.Z. Thompson retired as Head of Research and Development at ACADIA PHARMACEUTICALS INC.

Action: retired
Role: Head of Research and Development

Exact text from the filing

On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.

View on SEC.gov

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-197957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.